Nan Lin

4.7k total citations · 1 hit paper
106 papers, 1.7k citations indexed

About

Nan Lin is a scholar working on Molecular Biology, Hepatology and Oncology. According to data from OpenAlex, Nan Lin has authored 106 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 29 papers in Hepatology and 23 papers in Oncology. Recurrent topics in Nan Lin's work include Hepatocellular Carcinoma Treatment and Prognosis (15 papers), Liver physiology and pathology (14 papers) and RNA modifications and cancer (9 papers). Nan Lin is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (15 papers), Liver physiology and pathology (14 papers) and RNA modifications and cancer (9 papers). Nan Lin collaborates with scholars based in China, United States and Hong Kong. Nan Lin's co-authors include Ruiyun Xu, Mingxing Xu, Weidong Pan, Kunpeng Hu, Ronald Jansen, Mark Gerstein, Jizong Lin, Baolin Wu, Yi Lü and Hongyu Zhao and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Nan Lin

102 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer

2024 47 citations Yonger Chen, Jian Liang et al. Molecular Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nan Lin China	24	794	391	375	285	264	106	1.7k
Peng Hu China	20	733 0.9×	486 1.2×	119 0.3×	198 0.7×	200 0.8×	73	1.4k
Xiaoli Sun China	20	521 0.7×	209 0.5×	121 0.3×	406 1.4×	212 0.8×	59	1.6k
Bin Cheng China	25	1.1k 1.3×	674 1.7×	288 0.8×	409 1.4×	392 1.5×	103	2.3k
Young Ki Hong United States	19	620 0.8×	310 0.8×	225 0.6×	139 0.5×	239 0.9×	82	1.8k
Wang Li China	27	769 1.0×	470 1.2×	376 1.0×	208 0.7×	313 1.2×	108	2.0k
Valeria R. Mas United States	29	960 1.2×	501 1.3×	558 1.5×	507 1.8×	901 3.4×	113	2.6k
Simona Dima Romania	26	857 1.1×	518 1.3×	239 0.6×	291 1.0×	709 2.7×	160	2.3k
Jianming Zheng China	22	627 0.8×	452 1.2×	250 0.7×	397 1.4×	157 0.6×	86	1.5k
Chengjin Hu China	19	582 0.7×	311 0.8×	81 0.2×	216 0.8×	213 0.8×	50	1.2k
David Ho Hong Kong	21	1.0k 1.3×	643 1.6×	607 1.6×	187 0.7×	327 1.2×	35	2.3k

Countries citing papers authored by Nan Lin

Since Specialization

Citations

This map shows the geographic impact of Nan Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan Lin more than expected).

Fields of papers citing papers by Nan Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nan Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan Lin. The network helps show where Nan Lin may publish in the future.

Co-authorship network of co-authors of Nan Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Nan Lin. A scholar is included among the top collaborators of Nan Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nan Lin. Nan Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Qin, Nan Lin, Yuexi Chen, et al.. (2025). Machine learning-based prognostic model for bloodstream infections in hematological malignancies using Th1/Th2 cytokines. BMC Infectious Diseases. 25(1). 415–415. 1 indexed citations

Ren, Yupeng, Yuxuan Li, Hao Liang, et al.. (2025). CircRNA‐mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1/c‐Myc Axis. Advanced Science. 12(20). e2410591–e2410591. 4 indexed citations

Zhang, Shulin, Nan Lin, E Belcher, et al.. (2024). Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study. JCO Precision Oncology. 8(8). e2300266–e2300266. 1 indexed citations

Chen, Yonger, Jian Liang, Nan Lin, et al.. (2024). Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer. Molecular Cancer. 23(1). 196–196. 47 indexed citations breakdown →

Lin, Nan, et al.. (2023). Application of Long-Span Continuous Bridge Technology in Bridge Construction. 7(3). 7–12.

Wu, Qing, et al.. (2023). A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer. BMC Cancer. 23(1). 776–776. 7 indexed citations

Peng, Lin, Yanjie Li, Qiang Li, et al.. (2023). Distribution of per- and polyfluoroalkyl substances in blood, serum, and urine of patients with liver cancer and associations with liver function biomarkers. Journal of Environmental Sciences. 139. 418–427. 23 indexed citations

Lin, Nan, et al.. (2023). SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer. International Journal of Molecular Sciences. 24(18). 14212–14212. 7 indexed citations

Wu, Qing, et al.. (2023). Comprehensive research into prognostic and immune signatures of transcription factor family in breast cancer. BMC Medical Genomics. 16(1). 87–87. 3 indexed citations

10.

Lin, Nan, et al.. (2021). The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. Journal of Cancer Research and Clinical Oncology. 148(5). 1195–1210. 15 indexed citations

11.

McCorkle, J. Robert, J Górski, Jinpeng Liu, et al.. (2021). Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. PLoS ONE. 16(8). e0254205–e0254205. 18 indexed citations

12.

Lin, Nan, Jinpeng Liu, J. Castle, et al.. (2020). Genome-wide DNA methylation profiling in human breast tissue by Illumina TruSeq methyl capture EPIC sequencing and infinium methylationEPIC beadchip microarray. Epigenetics. 16(7). 754–769. 9 indexed citations

13.

Xu, Mingxing, et al.. (2020). Identification of CELSR2 as a novel prognostic biomarker for hepatocellular carcinoma. BMC Cancer. 20(1). 313–313. 13 indexed citations

14.

Peng, Hong, Zhiwei Zhou, Yu Guo, et al.. (2019). Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma. EBioMedicine. 46. 105–118. 17 indexed citations

15.

Bakulski, Kelly M., John Dou, Nan Lin, Stephanie J. London, & Justin A. Colacino. (2019). DNA methylation signature of smoking in lung cancer is enriched for exposure signatures in newborn and adult blood. Scientific Reports. 9(1). 4576–4576. 28 indexed citations

16.

Ma, Yong, et al.. (2018). Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma. OncoTargets and Therapy. Volume 11. 3659–3670. 4 indexed citations

17.

Lin, Jizong, et al.. (2015). Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis. OncoTargets and Therapy. 8. 2493–2493. 1 indexed citations

18.

Zhou, Yan, Nan Lin, & Baoxue Zhang. (2014). An iteration normalization and test method for differential expression analysis of RNA-seq data. BioData Mining. 7(1). 15–15. 7 indexed citations

19.

Lin, Nan, et al.. (2009). Deficient Proliferation of Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Chronic Hepatitis B Viral Infections and Cirrhosis of the Liver. Digestive Diseases and Sciences. 55(2). 438–445. 24 indexed citations

20.

Xu, Ruiyun, Bo Liu, & Nan Lin. (2004). Therapeutic effects of endoscopic variceal ligation combined with partial splenic embolization for portal hypertension. World Journal of Gastroenterology. 10(7). 1072–1072. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact